Janus Henderson Group’s DICE Therapeutics, Inc. Common Stock DICE Stock Holding History

Janus Henderson Group’s Portfolio DICE Stock Details DICE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-103,629	Closed	-$4.81M	–	2625
2023 Q2	$4.81M	Sell	103,629 -1,056,035	-91%	-$36.5M	﹤0.01%	872
2023 Q1	$33.2M	Buy	1,159,664 +66,246	+6%	+$1.96M	0.02%	467
2022 Q4	$34.1M	Sell	1,093,418 -2,177,878	-67%	-$71M	0.02%	456
2022 Q3	$66.3M	Buy	3,271,296 +1,561,976	+91%	+$28.5M	0.02%	452
2022 Q2	$26.5M	Sell	1,709,320 -97,598	-5%	-$1.68M	0.02%	515
2022 Q1	$34.6M	Sell	1,806,918 -32,311	-2%	-$577K	0.02%	601
2021 Q4	$45.6M	Sell	1,839,229 -24,978	-1%	-$732K	0.02%	576
2021 Q3	$58.6M	Buy	+1,864,207	New	+$63.5M	0.03%	503

Janus Henderson Group's DICE Position: Q3 2023 in Review

Janus Henderson Group sold out of DICE Therapeutics, Inc. Common Stock (DICE) in Q3 2023, closing a stake of 103,629 shares — an estimated $4.81M sold.

Janus Henderson Group first reported a position in DICE in Q3 2021 and held it in 8 quarters. The position peaked at $66.3M in Q3 2022. 0 funds tracked by Wall St. Rank hold DICE as of Q3 2023.

Janus Henderson Group reported no remaining DICE Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Janus Henderson Group sold 103,629 DICE Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $4.81M.
Janus Henderson Group first reported a position in DICE Therapeutics, Inc. Common Stock in Q3 2021 and held it in 8 quarters.
Janus Henderson Group's DICE Therapeutics, Inc. Common Stock position peaked at $66.3M in Q3 2022.
0 funds tracked by Wall St. Rank held DICE Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Janus Henderson Group's 13F filing for Q3 2023, filed 14 Nov 2023.